CN102089277B - 环状胺-1-甲酸酯衍生物及含有其的药物组合物 - Google Patents

环状胺-1-甲酸酯衍生物及含有其的药物组合物 Download PDF

Info

Publication number
CN102089277B
CN102089277B CN200980126428.8A CN200980126428A CN102089277B CN 102089277 B CN102089277 B CN 102089277B CN 200980126428 A CN200980126428 A CN 200980126428A CN 102089277 B CN102089277 B CN 102089277B
Authority
CN
China
Prior art keywords
manthanoate
hydroxy
methoxybenzene methyl
methyl formamyl
piperidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980126428.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102089277A (zh
Inventor
筑木保知
森江俊哉
中村高典
志水勇夫
宫内政德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN102089277A publication Critical patent/CN102089277A/zh
Application granted granted Critical
Publication of CN102089277B publication Critical patent/CN102089277B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN200980126428.8A 2008-05-07 2009-05-07 环状胺-1-甲酸酯衍生物及含有其的药物组合物 Expired - Fee Related CN102089277B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-121701 2008-05-07
JP2008121701 2008-05-07
PCT/JP2009/058644 WO2009136625A1 (fr) 2008-05-07 2009-05-07 Dérivé d’ester d’acide (amine cyclique)-1-carboxylique et composition pharmaceutique le contenant

Publications (2)

Publication Number Publication Date
CN102089277A CN102089277A (zh) 2011-06-08
CN102089277B true CN102089277B (zh) 2014-02-12

Family

ID=41264679

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980126428.8A Expired - Fee Related CN102089277B (zh) 2008-05-07 2009-05-07 环状胺-1-甲酸酯衍生物及含有其的药物组合物

Country Status (10)

Country Link
US (1) US8367835B2 (fr)
EP (2) EP2484664B1 (fr)
JP (1) JP4746713B2 (fr)
KR (1) KR101409651B1 (fr)
CN (1) CN102089277B (fr)
AU (1) AU2009245121B2 (fr)
CA (1) CA2721815C (fr)
ES (1) ES2433008T3 (fr)
HK (1) HK1168089A1 (fr)
WO (1) WO2009136625A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120081119A (ko) * 2009-09-04 2012-07-18 잘리커스 파마슈티컬즈 리미티드 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
PT3164117T (pt) 2014-07-03 2023-12-12 SpecGx LLC Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos
EP3307725A1 (fr) * 2015-06-11 2018-04-18 Basilea Pharmaceutica International AG Inhibiteurs de la pompe à efflux et utilisations thérapeutiques correspondantes
EP3856160A4 (fr) 2018-09-25 2022-07-06 SpecGx LLC Formes posologiques de capsules à libération immédiate anti-abus
GB2584471A (en) * 2019-06-05 2020-12-09 James Frank Thomas Peter Improvements in or relating to organic material
EP4206184A1 (fr) 2020-09-07 2023-07-05 Sumitomo Pharma Co., Ltd. Dérivé de phénol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100819A1 (fr) * 2001-06-11 2002-12-19 Dainippon Pharmaceutical Co., Ltd. Derives de n-arlyphenylacetamide et compositions medicinales contenant lesdits derives
JP2005504074A (ja) * 2001-09-13 2005-02-10 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 新規化合物
WO2006101318A1 (fr) * 2005-03-19 2006-09-28 Amorepacific Corporation Nouveaux composes, isomere de ceux-ci, ou sels de ceux-ci acceptables sur le plan pharmaceutique utilises en tant qu'antagonistes de recepteur vanilloide; et compositions pharmaceutiques contenant ces composes
JP2007502258A (ja) * 2003-08-14 2007-02-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーターとして用いるためのピペリジン／シクロヘキサンカルボキサミド誘導体
JP2007508255A (ja) * 2003-10-01 2007-04-05 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
JP2007509915A (ja) * 2003-10-29 2007-04-19 メルク シャープ エンド ドーム リミテッド 疼痛の治療のためにバニロイド１受容体（ｖｒ１）の機能を調節する４−フルオロ−４−（ピリジン−２−イル）ピペリジン−１−カルボキサミド誘導体及び関連化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
JP4250582B2 (ja) * 2004-09-30 2009-04-08 株式会社東芝 携帯端末
CN101203483A (zh) 2005-04-21 2008-06-18 大日本住友制药株式会社 N-取代的苯乙酰胺衍生物和包含该衍生物的药物组合物
WO2007003962A2 (fr) 2005-06-30 2007-01-11 Prosidion Limited Agonistes de gpcr
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100819A1 (fr) * 2001-06-11 2002-12-19 Dainippon Pharmaceutical Co., Ltd. Derives de n-arlyphenylacetamide et compositions medicinales contenant lesdits derives
JP2005504074A (ja) * 2001-09-13 2005-02-10 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 新規化合物
JP2007502258A (ja) * 2003-08-14 2007-02-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーターとして用いるためのピペリジン／シクロヘキサンカルボキサミド誘導体
JP2007508255A (ja) * 2003-10-01 2007-04-05 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
JP2007509915A (ja) * 2003-10-29 2007-04-19 メルク シャープ エンド ドーム リミテッド 疼痛の治療のためにバニロイド１受容体（ｖｒ１）の機能を調節する４−フルオロ−４−（ピリジン−２−イル）ピペリジン−１−カルボキサミド誘導体及び関連化合物
WO2006101318A1 (fr) * 2005-03-19 2006-09-28 Amorepacific Corporation Nouveaux composes, isomere de ceux-ci, ou sels de ceux-ci acceptables sur le plan pharmaceutique utilises en tant qu'antagonistes de recepteur vanilloide; et compositions pharmaceutiques contenant ces composes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JP特开平2005504074A 2005.02.10
JP特开平2007508255A 2007.04.05
JP特开平2007509915A 2007.04.19
JP特表2007502258A 2007.02.08
WO特开平2006101318A1 2006.09.28

Also Published As

Publication number Publication date
EP2277861A1 (fr) 2011-01-26
CN102089277A (zh) 2011-06-08
KR20110010620A (ko) 2011-02-01
HK1168089A1 (en) 2012-12-21
JPWO2009136625A1 (ja) 2011-09-08
EP2484664B1 (fr) 2013-09-04
US8367835B2 (en) 2013-02-05
EP2277861A4 (fr) 2012-05-02
ES2433008T3 (es) 2013-12-05
WO2009136625A1 (fr) 2009-11-12
CA2721815C (fr) 2014-06-10
KR101409651B1 (ko) 2014-06-18
JP4746713B2 (ja) 2011-08-10
AU2009245121B2 (en) 2013-08-01
AU2009245121A1 (en) 2009-11-12
CA2721815A1 (fr) 2009-11-12
US20120028937A1 (en) 2012-02-02
EP2484664A1 (fr) 2012-08-08

Similar Documents

Publication Publication Date Title
CN102089277B (zh) 环状胺-1-甲酸酯衍生物及含有其的药物组合物
DE60224404T2 (de) Substiuierte piperidine als melanocortinrezeptormodulatoren
EP2149560B1 (fr) Composé de tétrahydroisoquinoline 1-substituée
CN106715418A (zh) 治疗化合物及其使用方法
CA2822453C (fr) Nouveaux morphinanes utiles en tant qu'analgesiques
HUE028391T2 (en) Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands
CN108289886A (zh) 离子通道抑制化合物、药物制剂和用途
TWI823169B (zh) 黑皮質素受體促效劑化合物的晶形ⅲ及其製備方法
CN107835805A (zh) 被取代的苯甲酰胺和其使用方法
JP2023548161A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉｖおよびその製造方法
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
JP2023548163A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
JP2023548327A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
KR20070122541A (ko) Ｎ-치환 페닐아세트아미드 유도체 및 그것을 포함하는의약조성물
CN111574533A (zh) 柠檬苦素a环开环胺化衍生物或其药学上可接受的盐、制备方法及用途
KR20110017452A (ko) 무스칼린 수용체 길항제로서 활성인 신규한 화합물
CN107007596A (zh) 用于治疗创伤后应激障碍的方法
CN102317280A (zh) 具有胃动素受体激动活性的羟基吲哚衍生物
JP2023548162A (ja) 無定形のメラノコルチン－４受容体アゴニスト
CN108658843A (zh) 乙酰苄胺哌啶酰胺类衍生物及其作为脑神经保护剂的应用
WO2023133457A1 (fr) Nouveaux inhibiteurs de kalirine pour la régulation de la plasticité synaptique et le traitement de la douleur neuropathique
JP2024500966A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
TW202218659A (zh) 酚衍生物
CN106905238A (zh) 绿卡色林衍生物、其制法及减肥用途
JP2011102266A (ja) Ｎ−ベンジルアミド誘導体およびそれを含有する医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140212

Termination date: 20190507

CF01 Termination of patent right due to non-payment of annual fee